Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic seizures (FBDS) and received rituximab after relapsing or refractory disease. Both cases achieved sustained clinical remission of up to 15 and 56 months respectively. Rituximab use allowed withdrawal of corticosteroids and was well tolerated. Randomized clinical trials are needed in LGI1 encephalitis and other autoimmune encephalitides.

Original publication




Journal article


J Neuroimmunol

Publication Date





66 - 68


Autoantibody, Cognition, Encephalitis, LGI1, Rituximab, VGKC, Adult, Aged, Antibodies, Antibodies, Monoclonal, Murine-Derived, Encephalitis, Female, Humans, Immunologic Factors, Male, Proteins, Rituximab, Secondary Prevention, Seizures, Treatment Outcome